IT Type
Antibody-based IT
Description
The immunotoxin is comprised of a CD33- specific single chain Fv antibody fragment and a genetically engineered variant of Pseudomonas Exotoxin A (ETA).
Indication
Acute myelogenous leukemia (AML)
Classification
Immuntoxin; biobetter
Construction
scFv-ETA
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD33
Full Name
CD33 Molecule
Background
CD33 (CD33 Molecule) is a Protein Coding gene.
Diseases associated with CD33 include Gallbladder Lymphoma and Extracutaneous Mastocytoma.
Among its related pathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Innate Immune System.
Gene Ontology (GO) annotations related to this gene include receptor activity and carbohydrate binding.
An important paralog of this gene is SIGLEC6.
Alternative Names
CD33 Molecule; Sialic Acid-Binding Ig-Like Lectin 3; CD33 Antigen (Gp67); SIGLEC-3; SIGLEC3; Gp67;
Gene ID
Entrez Gene: 945
UniProt ID
UniProtKB: P20138
Antibody Clone
M195
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Type
scFv
Antibody Indication
Acute myelogenous leukemia (AML)
Toxic Moiety
Exfoliative toxin A (ETA)
Organism
Staphylococcus aureus
Family
Exfoliative toxin
Toxic MOA
The exfoliative toxins (ETs) also known as epidermolytic toxins, are serine proteases secreted by S. aureus that recognize and hydrolyze desmosome proteins. S. aureus ETs are serine proteases, which exhibit exquisite substrate specificity, and their mechanisms of action are extremely complex. However, the exact molecular mechanisms of ET‐causing epidermal blisters had long been unknown over the three decades.
The immunotoxin compound may be formulated with a carrier and administered into patients where the antibody portion binds to CD33-positive cells and kills those cells to provide an effective treatment for diseases such as human myeloid leukemia.
Acute myelogenous leukemia (AML)
